About Us

ELN-DAVID is the international working group for MRD ASSESSMENT and VALIDATION in AML and is part of the European LeukemiaNet (ELN).

Placing test tubes laboratory

The objective of ELN-DAVID is to promote measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) and related diseases through:

Scientific exchange and collaboration

Education and training

Standardization and quality control

Generation of clinical evidence for the use of MRD assessment in AML patients.

All diagnostic laboratory MRD techniques are subject to evaluation and standardization by ELN-DAVID including, but not limited to quantitative polymerase chain reaction (qPCR), multicolor flow cytometry (MFC), next-generation sequencing (NGS) and digital PCR (dPCR).

Executive Board

Christopher S. Hourigan ELN David

Christopher Hourigan

Chair
Francesco Buccisano ELN David

Francesco Buccisano

Vice-Chair

Christian Thiede

Treasurer
Prof. Dr. Michael Heuser ELN David

Michael Heuser

Past Chair

Jacqueline Cloos

Past Chair

Subcommittees

Woman ELN David

Sylvie Freeman

Flow-MRD
Richard Dillon ELN David

Richard Dillon

qPCR-MRD

Jacqueline Cloos

Flow-MRD
Man ELN David

Jad Othman

qPCR-MRD
Man ELN David

Wolfgang Kern

Flow-MRD
Man ELN David

Ing-Soo Tiong

qPCR

Christian Thiede

qPCR-MRD
Peter Valk ELN David

Peter Valk

NGS-MRD
Prof. Dr. Michael Heuser ELN David

Michael Heuser

NGS-MRD, Past-Chair
Man ELN David

Jesse Tettero

NGS-MRD

Konstanze Döhner

Clinical Aspects of MRD
Gail J. Roboz ELN David

Gail Roboz

Clinical Aspects of MRD

Advisory board

Gert Ossenkoppele

Marion Subklewe

Adriano Venditti ELN David

Adriano Venditti

Roland Walter ELN David

Roland Walter

Man ELN David

Brent Wood

Structure and Management

ELN-DAVID is governed by the executive board. The executive board consists of the chair, the vice-chair, the treasurer and subcommittee chairs for flow-, qPCR- and NGS-MRD, and the clinical subcommittee.

All members are approved by the executive board. The advisory board members and patient representatives are appointed by the executive board. Members, advisory board and patient representatives participate in the general assembly and elect the executive board members. The period of office of the members of the Board is three years.

The executive board may appoint administrative directors who legally represent ELN-DAVID in the participating countries.